Six weeks of Achillion’s ACH-3102 and Gilead Sciences’ Sovaldi (sofosbuvir) cured 100 percent of a small trial of people with genotype 1 of hepatitis C virus (HCV). The Phase II study of NS5A inhibitor ACH-3102 and the analog polymerase inhibitor Sovaldi included 12 people with genotype 1: seven with genotype 1a and five with genotype 1b. Read more: bit.ly/1BH86mi
ACH-3102 and Sovaldi Have 100% Hepati... - HFI Connect - Hep...
ACH-3102 and Sovaldi Have 100% Hepatitis C Cure Rate in 6 Weeks
Written by
mwright
To view profiles and participate in discussions please or .
Read more about...
Not what you're looking for?
You may also like...
Overwhelmed
Hi everyone, I'm new to this site and really just looking for somewhere I can talk to people that...
